(Unaudited)
 |
U.S. Product Sales (In millions)
|
| Avastin |
Rituxan |
Herceptin |
Avastin® (bevacizumab) is an anti-VEGF humanized antibody approved for use in combination with intravenous 5-fluorouracil-based
chemotherapy as a treatment for patients with first- or second-line metastatic cancer of the colon or rectum. It is also approved for use in combination with carboplatin and paclitaxel chemotherapy for the first-line treatment of unresectable, locally advanced, recurrent or metastatic non-squamous, non-small cell lung cancer and in combination with paclitaxel chemotherapy for the treatment of patients who have not received chemotherapy for metastatic HER2-negative breast cancer.¹
|
|
Rituxan® (Rituximab) is an
anti-CD20 antibody which we commercialize
with Biogen Idec Inc. It
is approved for several forms of
CD20-positive, B-cell non-Hodgkin's
lymphoma. Rituxan is also
approved in combination with
methotrexate for reducing signs
and symptoms and slowing the
progression of structural damage
in adult patients with moderately-to-severely active rheumatoid
arthritis who have had an inadequate
response to one or more tumor
necrosis factor antagonist therapies.
|
|
Herceptin® (Trastuzumab) is a
humanized anti-HER2 antibody
approved in combination with
paclitaxel and as a single agent in
second- and third-line therapy
for patients with HER2-positive
metastatic breast cancer. Herceptin
is also approved as an
adjuvant treatment in HER2-positive,
node-positive breast cancer
in combination with doxorubicin,
cyclophosphamide, and paclitaxel
and HER2-overexpressing node-negative
or node-positive breast
cancer, following multi-modality
anthracycline-based therapy.
|
|
| Lucentis |
Xolair |
Tarceva |
Lucentis® (ranibizumab injection)
is an anti-VEGF antibody fragment
approved for the treatment of neovascular
(wet) age-related macular
degeneration.
|
|
Xolair® (Omalizumab) for Subcutaneous
Use is a humanized anti-IgE
antibody which we commercialize
with Novartis Pharma AG. Xolair
is approved for adults and adolescents
(12 years of age and above)
with moderate-to-severe persistent
asthma who have a positive
skin test or in vitro reactivity
to a perennial aeroallergen and
whose symptoms are inadequately
controlled with inhaled corticosteroids.
|
|
Tarceva® (erlotinib), which we
commercialize with OSI Pharmaceuticals,
Inc., is a small-molecule
tyrosine kinase inhibitor of the
HER1/epidermal growth factor
receptor signaling pathway. Tarceva
is approved for the treatment
of patients with locally advanced
or metastatic non-small cell lung
cancer after failure of at least one
prior chemotherapy regimen. It is
also approved, in combination with
gemcitabine chemotherapy, for the
first-line treatment of patients with
locally advanced, unresectable or
metastatic pancreatic cancer.
|
|
| Nutropin Products |
Thrombolytics |
Pulmozyme |
Nutropin® (somatropin [rDNA
origin] for injection) and Nutropin
AQ® are growth hormone products
approved for the treatment
of growth hormone deficiency
in children and adults, growth
failure associated with chronic
renal insufficiency prior to kidney
transplantation, short stature
associated with Turner syndrome
and long-term treatment of idiopathic
short stature.
|
|
Activase® (alteplase, recombinant)
is a tissue plasminogen activator
(or t-PA) approved for the treatment
of acute myocardial infarction
(heart attack), acute ischemic stroke
(blood clots in the brain) within
three hours of the onset of symptoms,
and acute massive pulmonary
embolism (blood clots in the lungs).
TNKase® (tenecteplase) is a modified
form of t-PA approved for the
treatment of acute myocardial
infarction (heart attack). Cathflo®
Activase® (alteplase, recombinant)
is a t-PA approved in adult and
pediatric patients for the restoration
of function to central venous access
devices that have become occluded
due to a blood clot.
|
|
Pulmozyme® (dornase alfa, recombinant)
is an inhalation solution
approved for the treatment of cystic
fibrosis.
|
|
| Raptiva |
|
|
Raptiva® (efalizumab) is a humanized
anti-CD11a antibody approved
for the treatment of chronic moderate-to-severe plaque psoriasis in
adults age 18 or older who are candidates
for systemic therapy
or phototherapy.
|
|
|
|
¹ On February 22, 2008, Genentech received accelerated approval for Avastin in combination with paclitaxel for the treatment of patients who have not received chemotherapy for metastatic HER2-negative breast
cancer. The effectiveness of Avastin in metastatic breast cancer is based on an improvement in progression-free survival. Avastin is not indicated for patients with breast cancer that has progressed following
anthracycline and taxane chemotherapy administered for metastatic disease. Currently, no data are available that demonstrate an improvement in disease-related symptoms or increased survival with Avastin in
breast cancer.
